| Literature DB >> 29618459 |
Brady Hunt1, José Humberto Tavares Guerreiro Fregnani2, Richard A Schwarz1, Naitielle Pantano2, Suelen Tesoni2, Júlio César Possati-Resende2, Marcio Antoniazzi2, Bruno de Oliveira Fonseca2, Graziela de Macêdo Matsushita2, Cristovam Scapulatempo-Neto2, Ligia Kerr2, Philip E Castle3, Kathleen Schmeler4, Rebecca Richards-Kortum5.
Abstract
Cervical cancer is a leading cause of death in underserved areas of Brazil. This prospective randomized trial involved 200 women in southern/central Brazil with abnormal Papanicolaou tests. Participants were randomized by geographic cluster and referred for diagnostic evaluation either at a mobile van upon its scheduled visit to their local community, or at a central hospital. Participants in both arms underwent colposcopy, in vivo microscopy, and cervical biopsies. We compared rates of diagnostic follow-up completion between study arms, and also evaluated the diagnostic performance of in vivo microscopy compared with colposcopy. There was a 23% absolute and 37% relative increase in diagnostic follow-up completion rates for patients referred to the mobile van (102/117, 87%) compared with the central hospital (53/83, 64%; P = 0.0001; risk ratio = 1.37, 95% CI, 1.14-1.63). In 229 cervical sites in 144 patients, colposcopic examination identified sites diagnosed as cervical intraepithelial neoplasia grade 2 or more severe (CIN2+; 85 sites) with a sensitivity of 94% (95% CI, 87%-98%) and specificity of 50% (95% CI, 42%-58%). In vivo microscopy with real-time automated image analysis identified CIN2+ with a sensitivity of 92% (95% CI, 84%-97%) and specificity of 48% (95% CI, 40%-56%). Women referred to the mobile van were more likely to complete their diagnostic follow-up compared with those referred to a central hospital, without compromise in clinical care. In vivo microscopy in a mobile van provides automated diagnostic imaging with sensitivity and specificity similar to colposcopy. Cancer Prev Res; 11(6); 359-70. ©2018 AACR. ©2018 American Association for Cancer Research.Entities:
Mesh:
Year: 2018 PMID: 29618459 PMCID: PMC5984709 DOI: 10.1158/1940-6207.CAPR-17-0265
Source DB: PubMed Journal: Cancer Prev Res (Phila) ISSN: 1940-6215